Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD5863 |
| Synonyms | |
| Therapy Description |
AZD5863 is a bispecific T-cell engager targeting CLDN18.2 and CD3, which potentially induces T-cell dependent cellular cytotoxicity and tumor growth inhibition (J ImmunoTherapy Cancer 2023;11 (Suppl_1):1169). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD5863 | AZD 5863|AZD-5863 | CD3 Antibody 119 CLDN18.2 Antibody 23 | AZD5863 is a bispecific T-cell engager targeting CLDN18.2 and CD3, which potentially induces T-cell dependent cellular cytotoxicity and tumor growth inhibition (J ImmunoTherapy Cancer 2023;11 (Suppl_1):1169). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06005493 | Phase Ib/II | AZD5863 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NLD | GBR | FRA | 4 |